Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
“OK, So what’s Next? Topline data from the superior efficacy interim analysis should represent the next major milestone in the Mino-Lok trial. It is expected, based on the current events rate and enrollment, to occur in the first half of 2020. This second interim analysis is looking at efficacy, or in this case, superiority. The plan is to evaluate the data at 69 events, or 75% of the total events anticipated at ~108 patients.”
Citius is a client, see all CTXR reports for disclosure and disclaimer details.
